FDA Testosterone Warning: 2015 Drug Safety Communication & TRT

Last Updated: APRIL 2024

Men with low total testosterone levels face significantly increased health risks. A meta-analysis of 11 prospective studies found that men with low total testosterone had a 1.35-fold increased risk of all-cause mortality and a 1.25-fold increased risk of cardiovascular mortality compared to men with normal testosterone levels (Andrology, 2015). Despite these clear associations, the journey to widely accepted testosterone replacement therapy (TRT) has been fraught with controversy, largely fueled by regulatory actions. In 2015, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) that cast a long shadow over testosterone products, mandating label changes to include warnings about potential cardiovascular risks. This decision, though intended to safeguard public health, inadvertently created a climate of fear and gatekeeping, making it harder for men with legitimate hypogonadism to access life-changing treatment. Now, a decade later, groundbreaking research has led to a significant reversal, reshaping our understanding of TRT’s safety profile.

The 2015 FDA Drug Safety Communication: A Period of Caution

The mid-2010s saw a dramatic increase in testosterone prescriptions, often driven by aggressive direct-to-consumer advertising for “Low T.” This surge, coupled with the rise of “Low T clinics,” prompted regulatory scrutiny. The FDA’s 2015 Drug Safety Communication was a direct response to these trends, citing concerns about the widespread use of testosterone products, especially for “age-related low T” without clear medical necessity.

The communication mandated new labeling on all approved testosterone products. It warned of an increased risk of heart attack, stroke, and death in men taking testosterone. Furthermore, it explicitly stated that testosterone was only approved for men with hypogonadism caused by specific medical conditions, not for general age-related decline. This effectively narrowed the on-label indication for TRT, pushing many prescriptions into an “off-label” gray area and causing significant apprehension among healthcare providers.

The FDA’s decision was heavily influenced by several observational studies published around that time. Key among them were:

• Vigen et al. (2013) JAMA: This study reported an increased risk of death, myocardial infarction, or stroke in men undergoing coronary angiography who initiated testosterone therapy.
• Finkle et al. (2014) PLoS ONE: This research linked testosterone therapy to an increased risk of non-fatal myocardial infarction in older men and in younger men with pre-existing heart disease.

These studies, while raising important questions, were observational and retrospective, meaning they could only show association, not causation. They often lacked control for crucial confounding factors like pre-existing conditions, lifestyle, and dosage variations. This methodological limitation became a major point of contention within the medical community.

The consequence for patients was often significant. Many men experiencing debilitating symptoms of hypogonadism, whose testosterone levels fell into ambiguous ranges—such as the historically problematic lower limit of 264 ng/dL, derived from a 1970s study population that included sick and elderly individuals—found themselves unable to secure treatment. The focus shifted from treating symptoms and optimizing health to adhering to restrictive, often arbitrary, diagnostic criteria.

Challenging the 2015 Stance: The Need for Robust Data

The medical and scientific community quickly recognized the limitations of the data supporting the 2015 FDA warning. Observational studies, by their nature, are prone to bias. For instance, men with existing cardiovascular issues might be more likely to have low testosterone, or they might be more likely to have their low testosterone diagnosed and treated in the first place, creating a “channeling bias.” What was desperately needed was a large-scale, prospective, randomized, placebo-controlled trial designed specifically to assess the cardiovascular safety of testosterone therapy.

Without such data, clinicians were left in a difficult position: weigh the symptomatic benefits of TRT against a poorly quantified, but officially warned, cardiovascular risk. Many recognized that untreated hypogonadism itself is a significant risk factor for cardiovascular disease, metabolic syndrome, and all-cause mortality. The lack of clarity fostered a conservative prescribing environment, potentially denying beneficial therapy to men who needed it most.

The TRAVERSE Trial and the 2025 Reversal

The demand for definitive evidence led to the design and execution of the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Safety (TRAVERSE) trial. This landmark study, sponsored by the manufacturers of testosterone gels, was a large, multi-center, randomized, double-blind, placebo-controlled trial specifically designed to address the cardiovascular safety concerns.

Published in The New England Journal of Medicine in 2023, the TRAVERSE trial enrolled 5,204 men aged 45 to 80 years with pre-existing or high risk of cardiovascular disease and documented hypogonadism (two morning total testosterone levels below 300 ng/dL). Participants were randomized to receive either a testosterone gel or a placebo gel, with treatment periods averaging 3